Clinical Trials

31 enrolled 15 charts

Small Cell Lung Carcinoma

NCT04397003 2025-10-22

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

6 enrolled

Small Cell Lung Carcinoma

NCT04472949 2025-10-01

Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).

46 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05796089 2025-08-26

CHEST RT

35 enrolled

Small Cell Lung Carcinoma

NCT05617963 2025-06-15

DURVALUNG

Phase 2 Recruiting

100 enrolled

Phase 2 Enrolling by invitation

Small Cell Lung Carcinoma

NCT06419179 2025-05-20

GUIDANCE

29 enrolled

Small Cell Lung Carcinoma

NCT04951115 2024-11-26

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Phase 2 Terminated

6 enrolled 13 charts

Small Cell Lung Carcinoma

NCT05572476 2024-06-05

LURBIMUNE

Phase 2 Withdrawn

Small Cell Lung Carcinoma

NCT06223711 2024-04-05

Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC

Phase 2 Recruiting

43 enrolled

Small Cell Lung Carcinoma

NCT04610684 2024-03-13

Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases

Phase 2 Terminated

3 enrolled 13 charts

CNSThoracic

Brain Neoplasms, Small Cell Lung Carcinoma

NCT05092412 2024-01-12

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

30 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04361825 2024-01-03

SUKSES-N4

Phase 2 Completed

42 enrolled

Small Cell Lung Carcinoma

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

441 enrolled

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05484583 2022-08-05

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

Phase 2 Not yet recruiting

58 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05245994 2022-02-18

An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese

60 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

Phase 2 Completed

18 enrolled 13 charts

Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

40 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

33 enrolled

Small Cell Lung Carcinoma

NCT03585998 2020-03-02

Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer

51 enrolled